MedTrace Logo

Definition, Quantification, and Utility of Biomarkers of Repetitive Brain Injury in Predicting Concussion and Other Long-Term Injury Risks in Patients With Atrial Fibrillation (Concussion AF)

NCT03875131 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-05-24

No results posted yet for this study

Summary

This is a prospective clinical study designed to evaluate biomarkers of brain injury and dementia incidence and moderate cognitive decline rates in moderate- to high-risk atrial fibrillation patients that undergo standard of care atrial fibrillation management.

Conditions

  • Cognitive Change

Interventions

OTHER

Biomarkers of Dementia and Cognitive Decline

Biomarkers will be obtained at baseline, 6, 12, 18, and 24 months. The six questionnaires listed below will be administered at the baseline visit, and repeated at the 24-month visit to evaluate cognitive decline. * Mini-Mental Status Evaluation * Hachinski Ischemic Scale * Cognitive Subscale of Alzheimer's Disease Assessment Scale * Disability Assessment for dementia * Quality of life improvement as assessed by: * Minnesota Living with Heart Failure Scale * Anti-Clot Treatment Scale (ACTS) Quality of Life Survey

Sponsors & Collaborators

  • Intermountain Health Care, Inc.

    lead OTHER

Principal Investigators

  • Jared Bunch, MD · Intermountain Medical Center

Eligibility

Min Age
65 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-15
Primary Completion
2022-10-24
Completion
2022-10-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03875131 on ClinicalTrials.gov